|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9647
|
|
pubmed:dateCreated |
2008-10-22
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Diabetic retinopathy remains a leading cause of visual loss in people of working age. We examined whether candesartan treatment could slow the progression and, secondly, induce regression of retinopathy in people with type 2 diabetes.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1474-547X
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
18
|
|
pubmed:volume |
372
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1385-93
|
|
pubmed:meshHeading |
pubmed-meshheading:18823658-Adult,
pubmed-meshheading:18823658-Aged,
pubmed-meshheading:18823658-Angiotensin II Type 1 Receptor Blockers,
pubmed-meshheading:18823658-Benzimidazoles,
pubmed-meshheading:18823658-Diabetes Mellitus, Type 2,
pubmed-meshheading:18823658-Diabetic Retinopathy,
pubmed-meshheading:18823658-Dose-Response Relationship, Drug,
pubmed-meshheading:18823658-Double-Blind Method,
pubmed-meshheading:18823658-Endpoint Determination,
pubmed-meshheading:18823658-Female,
pubmed-meshheading:18823658-Humans,
pubmed-meshheading:18823658-Hypertension,
pubmed-meshheading:18823658-Hypoglycemic Agents,
pubmed-meshheading:18823658-Male,
pubmed-meshheading:18823658-Middle Aged,
pubmed-meshheading:18823658-Severity of Illness Index,
pubmed-meshheading:18823658-Tetrazoles
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial.
|
|
pubmed:affiliation |
Department of Ophthalmology, Odense University Hospital, Odense, Denmark.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
